Displaying One Session

Medscape Oncology Global - Targets of Antibody-Drug Conjugates in NSCLC: Diagnostics, Emerging Therapies, and Future Prospects (ID 140)

Time
18:30 - 20:00

Personalizing Treatment in NSCLC: Recent Developments (ID 6129)

Novel ADC Targets in NSCLC: Rationale and Diagnostic Considerations (ID 6131)

Which Patients May Benefit From Emerging ADCs in NSCLC: Explaining the Clinical Trial Data (ID 6132)

Preparing the Clinics and Future Prospects (ID 6133)

Q&A Session (ID 6136)

Concluding Remarks (ID 6139)